类风湿性关节炎的基础研究与进展.ppt

  1. 1、本文档共48页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
CIA大鼠的骨保护作用-MRI Refer:Fang Du,liang-jing Lv,et al. T-614,a novel immunomodulator,attenuates inflammation and articular damage in collagen induced arthritis. Arthritis Research Therapy 2008,10:R136 a: normal rats; b: CIA rats treated with vehicle; c: CIA rats treated with MTX; d:CIA rats treated with nimesulide e/f: CIA rats treated with T614; g: CIA rats treated with T-614 and MTX a b c d e f g soft tissue swelling (yellow arrow) and localization of bone marrow edema (yellow triangle) MRI检测结果:艾得辛能够几乎完全抑制CIA的炎症和骨髓内水肿。 影像学评估 –X线和CT T-614 offered significant protection against joint damage a b c d e f g A Naive Vehicle MTX nimesulide T614 (5) T614 (20) MTX+T614(10) a b c d e f g C X线平片和CT检测结果显示:艾得辛还能够显著抑制骨吸收和关节破坏。 目录 病因 ---基因因素 ---环境因素 病机 ---RA滑膜炎 ---RA骨侵蚀 基础研究引导治疗的发展 基础研究引导RA的靶向治疗 T cell APCs B cell or macrophage Synoviocytes Pannus Articular cartilage Chondrocytes HLA -DR Production of collagenase and other neutral proteases Abs Immune complexes Articular cartilage Production of collagenase and other neutral proteases T cell APCs Macrophage B cell B cell cytokines Osteoclast Complements TNF-? IL-1 IL-6 RA治疗方法的递进 Drugs Objectives Concepts 1980s MTX, D-PA, Gold... Signs symptoms pyramid 1990s DMARDs ? joint damage Combination Leflunomide 2000 Bi-DMARDs Prevent joint damage Early treatment Stop joint damage Tight control 2008 Remission Early intensive ttt 靶向治疗使RA的治疗目标更高 Target Name Function Anti-TNF Etanercept Soluable TNF receptor Infiximab Chimeric anti-TNF Mab Adalimumab Fully human anti-TNF Mab Golimumab Fully human anti-TNF Mab Certolizumab Pegol Pegylated Fab fragment of a humanized MoAb against TNF Anti-IL-1 anakinra IL-1ra Rilonacept Dimeric fusion protein: extracellular IL-1R IgG1-Fc Anti-IL-6 Tocilizumab Humanized anti-human IL-6 receptor antibody Ustekinumab MoAb against receptor (p40) of IL-12 IL-23, Effective for PsA (phase III) B cells Rituximab anti-CD20 monoclonal antibody that selectively dep

文档评论(0)

189****6140 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档